

Degeneración macular
Diabetes
Sistema nervioso
Sistema inmune

1



asebio

Vigilancia Tecnológica

3º trimestre 2013

Cada año el sector biotecnológico adquiere una mayor importancia, lo que lo sitúa como uno de los sectores clave para la economía española. Según los últimos datos del Instituto Nacional de Estadística del año 2011, el número de empresas que afirman realizar actividades biotecnológicas en España alcanza las 3.025 empresas (lo que supondría un incremento de 1.310 compañías con respecto al año anterior) y las que se dedican exclusivamente a la biotecnología llegan a las 660.

Además, en el año 2011 las cifra de facturación y empleo del sector biotecnológico español han crecido a tasas del 25%. Este gran avance se interpreta como un síntoma de consolidación del sector, debido a la visibilidad creciente que está adquiriendo la biotecnología como fuente de innovación y de mejora de la competitividad en múltiples sectores de los denominados tradicionalmente maduros.

De acuerdo con los datos publicados en los últimos cuatro años, el número de solicitudes de patentes en el sector biotecnológico experimenta una tendencia claramente positiva con un crecimiento del 146,3% en los cuatro últimos años. Esta evolución manifiesta no solo que el sector biotecnológico es un sector en auge sino además la importancia que éste le concede a la Propiedad Industrial como vía para recuperar la inversión.

Por otra parte la Oficina Española de Patentes y Marcas (OEPM), dentro de su Estrategia 2012-2014 en materia de Propiedad Industrial para empresas y emprendedores, contempla como una de las líneas estratégicas

“aumentar la concienciación empresarial sobre la Propiedad Industrial” implicando a elementos multiplicadores, como las Plataformas Tecnológicas Españolas.

Desde el pasado año la OEPM ha venido colaborando activamente con las referidas Plataformas poniendo a su disposición todos los servicios de formación, información tecnológica, difusión y comunicación de que dispone con objeto de que éstos puedan ser utilizados por las empresas, investigadores, y organizaciones que integran estas Plataformas, con el fin de que la tecnología que generen sea una tecnología con valor, que permita el retorno financiero y mejore la competitividad de las empresas y su internacionalización.

Este nuevo Boletín de Vigilancia Tecnológica en Biotecnología aplicada al sector sanitario surge de esta colaboración entre la OEPM y ASEBIO como miembro de la Plataforma Tecnológica Española de Mercados Biotecnológicos.

Con objeto de que este Boletín pudiera resultar de interés al mayor número de empresas y organizaciones del sector, y después de los contactos realizados por ASEBIO entre sus asociados, resultaron numerosas las líneas de actuación propuestas. Incluir en un único Boletín distintos subsectores (Biotecnología Sanitaria, Agrícola e Industrial), implicaba por una parte el análisis de un número muy elevado de patentes, y por otra la consulta final por parte de los usuarios de un Boletín con un número excesivo de patentes y por tanto de no fácil lectura.

Por ello se decidió finalmente empezar con un sector muy específico, Biotecnología aplicada al sector sanitario y dentro de este con cuatro objetos técnicos concretos (Sistema Nervioso, Sistema Inmune, Diabetes y Degeneración Macular), sin menoscabo de que posteriormente pudieran ser analizados otros sectores.

Estos Boletines trimestrales, como el resto de los elaborados por la OEPM, ofrecerán una información puntual, esquemática y de rápida lectura sobre una selección de las últimas


patentes biotecnológicas publicadas en el mundo relativas a las cuatro líneas de investigación comentadas. También incluirán breves noticias sobre actividades realizadas por la OEPM que puedan resultar de interés a los usuarios.

Se puede acceder al listado de solicitudes de patentes para cada grupo analizado pulsando sobre las imágenes que aparecen a continuación.


Contenido



Degeneración
Macular



Diabetes



Sistema Nervioso



Sistema Inmune

Degeneración Macular

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013124659 A1</u> <u>20130829</u>	UCL BUSINESS PLC [GB]	Biomarker for age-related macular degeneration (amd)
<u>WO2013123292 A1</u> <u>20130822</u>	SCHEPENS EYE RES INST [US]	Phenotype profile of human retinal progenitor cells
<u>WO2013113820 A1</u> <u>20130808</u>	ESBATECH A NOVARTIS COMPANY LLC [CH]	Antibody-containing sustained-release formulation for ocular administration
<u>WO2013096868 A2</u> <u>20130627</u>	CHILDRENS MEDICAL CENTER [US]	Saposin-a derived peptides and uses thereof
<u>WO2013093762 A1</u> <u>20130627</u>	NOVARTIS AG [CH]	Compositions and methods for antibodies targeting factor P
<u>WO2013067098 A1</u> <u>20130510</u>	APEXIGEN INC [US]	Anti-kdr antibodies and methods of use
<u>WO2013056851 A2</u> <u>20130425</u>	ESBATECH A NOVARTIS COMPANY LLC [CH]	Stable multiple antigen-binding antibody
<u>WO2013055998 A1</u> <u>20130418</u>	SEGUGEN S L; UNIV DE NAVARRA; CONSEJO SUPERIOR INVESTIGACION [ES]	Anti-htra1 antibodies and methods of use
<u>ES2399897 A1</u> <u>20130404</u>	SEGUGEN S L; UNIV DE NAVARRA; CONSEJO SUPERIOR INVESTIGACION [ES]	Método para la predicción del riesgo de desarrollar la enfermedad de degeneración macular asociada a la edad en la población española
<u>WO2013005053 A2</u> <u>20130110</u>	CELL THERAPY LTD [GB]; HOUZE THOMAS AVERELL [SE]; EVANS MARTIN JOHN [GB]; REGINALD AJAN [GB]; PIEPER INA LAURA [GB]; PERKINS BRIAN [GB]	Progenitor cells of mesodermal lineage
<u>WO2012061377 A1</u> <u>20120510</u>	PSIVIDA INC [US]; ASHTON PAUL [US]; CANHAM LEIGH T [GB]; BARNETT CHRISTIAN [GB]; PSIMEDICA LTD [GB]; PSIVIDA CORP [US]	Bioerodible silicon-based devices for delivery of therapeutic agents

Diabetes

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013124463 A1 20130829</u>	IMMUNDIAGNOSTIK AG [DE]; DSCHIETZIG THOMAS [DE]	Relaxin for treating patients afflicted of impaired glucose tolerance
<u>WO2013123214 A1 20130822</u>	DEPUY SYNTHES PRODUCTS LLC [US]	Methods and composition related to brown adipose-like cells
<u>WO2013123094 A2 20130822</u>	UNIV CALIFORNIA [US]	Systemic delivery and regulated expression of paracrine genes for cardiovascular diseases and other conditions
<u>WO2013121034 A1 20130822</u>	INST NAT SANTE RECH MED [FR]	Methods and pharmaceutical compositions for reducing adipose tissue inflammation
<u>WO2013118857 A1 20130815</u>	UNIV OSAKA [JP]; SHIONOGI & CO [JP]	Antisense oligonucleotide for acsl1
<u>WO2013118799 A1 20130815</u>	TOYO BOSEKI [JP]	Novel glucose dehydrogenase
<u>WO2013117776 A1 20130815</u>	FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD [ES]; INST DE SALUD CARLOS III; CUESTA MUÑOZ ANTONIO LUIS [ES]	Glucokinase enzymes with increased activity and use thereof in the treatment and/or prevention of diabetes mellitus
<u>EP2626704 A1 20130814</u>	SOYLEMEZ MEHMET ALI [TR]	Diagnosis and complication risk assessment of pancreatic diabetes within normal value ranges of leucocytes using procalcitonin
<u>WO2013115504 A1 20130808</u>	POSTECH ACAD IND FOUND [KR]	Pharmaceutical composition for preventing or treating diabetes containing tenc1 expression or activity suppressor
<u>WO2013113008 A1 20130801</u>	AMGEN INC [US]	Growth differentiation factor 15 (gdf-15) polypeptides
<u>WO2013112602 A1 20130801</u>	UNIV MASSACHUSETTS [US]	Soluble manf in pancreatic beta-cell disorders
<u>WO2013111823 A1 20130801</u>	J OIL MILLS INC [JP]; TAKAHARA YOSHIYUKI [JP]	Method for producing sphingoid base-containing extract
<u>WO2013110245 A1 20130801</u>	UNIV HONG KONG CHINESE [CN]	Biomarkers for diabetes
<u>WO2013110050 A1 20130725</u>	UNIV SOUTH DAKOTA [US]; TUMMALA HEMACHAND [US]; KUMAR SUNNY [US]	Inulin and inulin acetate formulations

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013109974 A2 20130725</u>	GENZYME CORP [US]	Anti-cxcr3 antibodies
<u>WO2013109819 A1 20130725</u>	GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]	Anti-lrp5 antibodies and methods of use
<u>WO2013109488 A1 20130725</u>	GLAXOSMITHKLINE INTELLECTUAL PROPERTY NO 2 LTD [GB]; PAULIK MARK ANDREW [US]; HODGE REBECCA JANE [US]	Compositions and methods for treating diabetes and/or obesity
<u>WO2013109342 A1 20130725</u>	UNIV CINCINNATI [US]	Method of treating diabetes using non-glycosylated apolipoprotein a-iv
<u>WO2013106851 A2 20130718</u>	EASTERN VIRGINIA MED SCHOOL [US]	Syncollin, pancreatic triacylglycerol lipase, and other biomarkers for diabetes
<u>WO2013106643 A2 20130718</u>	UNIV YALE [US]; GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEV LTD [GB]; CAMBRIDGE ENTPR LTD UNIVERSITY OF CAMBRIDGE [GB]	Compounds & methods for the enhanced degradation of targeted proteins & other polypeptides by an e3 ubiquitin ligase
<u>WO2013106485 A2 20130718</u>	SCRIPPS RESEARCH INST [US]; BAZIRGAN OMAR A [US]; MAO HONGYUAN HELEN	Ultralong complementarity determining regions and uses thereof
<u>WO2013106437 A1 20130718</u>	ANCHOR THERAPEUTICS INC [US]	Apj receptor compounds
<u>WO2013103632 A1 20130711</u>	QUARK PHARMACEUTICALS INC [US]; ERLICH SHAI [US]; THOMPSON JAMES D [US]; OZDEN RABIA [US]	Double-stranded RNA compounds to casp2 and uses thereof
<u>WO2013103226 A1 20130711</u>	SNU R&DB FOUNDATION [KR]	Marker for early diagnosis of diabetic retinopathy and usage for same
<u>WO2013102921 A2 20130711</u>	SANZYME LTD [IN]	Hcg - newer treatment modality for type 2 diabetes mellitus (t2dm)
<u>WO2013100793 A1 20130704</u>	MARTYNOV ARTUR VIKTOROVICH [UA]; FARBER BORIS SLAVINOVICH [RU]; FARBER SOF YA BORISOVNA [RU]	Insulsin derivative with antihyperglycemic activity and method for the production thereof
<u>WO2013100741 A1 20130704</u>	UNIV KONKUK IND COOP CORP [KR]	Gintonin having ginseng major latex-like protein and ginseng rnase-like major storage protein as constituent proteins
<u>WO2013100292 A1 20130704</u>	UNIV YEUNGNAM IACF [KR]; CHO KYUNG-HYUN [KR]	Composition for preventing or treating diabetes or diabetic complications
<u>WO2013098333 A1 20130704</u>	BIONEST LTD [IE]	Combination of growth factors, cytokines, antibacterial/antiviral factors, stem cell stimulating factors, complement proteins c3a/c4a, immunoglobulins and chemotactic factors

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013095953 A1</u> <u>20130627</u>	JANSSEN BIOTECH INC [US]	Differentiation of human embryonic stem cells into single hormonal insulin positive cells
<u>WO2013094723 A1</u> <u>20130627</u>	ASTELLAS PHARMA INC [JP]	Novel anti-human ctgf antibody
<u>WO2013093707 A1</u> <u>20130627</u>	RINAT NEUROSCIENCE CORP [US]	Human growth hormone receptor antagonist antibodies and methods of use thereof
<u>WO2013090454 A2</u> <u>20130620</u>	RECEPTOS INC [US]	Novel glp-1 receptor modulators
<u>WO2013086786 A1</u> <u>20130620</u>	QIN SHULIN [CN]	Compound and composition having hypoglycemic effect and use thereof
<u>WO2013086443 A1</u> <u>20130613</u>	AMGEN INC [US]	Agonistic human Icat antigen binding proteins and their use in therapy
<u>WO2013083753 A2</u> <u>20130613</u>	PASTEUR INSTITUT [FR]; PATHOQUEST [FR]; ECOLE NATIONALE VETERINAIRE D ALFORT [FR]	Identification of a swine parecho-like virus and applications
<u>WO2013083720 A1</u> <u>20130613</u>	CENTRE NAT RECH SCIENT [FR]; UNIV NICE SOPHIA ANTIPOLIS [FR]	Antibodies anti-spla2-x and uses thereof
<u>WO2013082158 A1</u> <u>20130606</u>	MIMEDX GROUP INC [US]; SPENCER RANDALL [US]; RAY STEVEN [US]	Shredded tissue grafts and methods for making and using the same
<u>WO2013082116 A1</u> <u>20130606</u>	PHASEBIO PHARMACEUTICALS INC [US]	Therapeutic agents comprising insulin amino acid sequences
<u>WO2013080184 A1</u> <u>20130606</u>	CONSEJO NAC INVEST CIENT TEC [AR]; INIS BIOTECH LLC [US]	Chimeric protein comprising proinsulin fused to thioredoxin
<u>WO2013078122 A1</u> <u>20130530</u>	HARVARD COLLEGE [US]	Diabetes diagnosis through the detection of glycated proteins in urine
<u>WO2013074681 A1</u> <u>20130523</u>	ADVANCED CELL TECH INC [US]	Pharmaceutical preparations of human rpe cells and uses thereof
<u>WO2013074557 A1</u> <u>20130523</u>	REGENERON PHARMA [US]	Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and/or activin a
<u>WO2013073698 A1</u> <u>20130523</u>	TOKYO METROPOLITAN INST OF MEDICAL SCIENCE [JP]	Cxcr4 activity inhibiting peptide and application thereof

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013072512 A1</u> <u>20130523</u>	ADRENOMED AG [DE]	Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy
<u>WO2013071715 A1</u> <u>20130523</u>	NANJING YOKO BIOMEDICAL R & D LTD [CN]; NANJING XINGANG MEDICAL CO LTD [CN]; NANJING YOKO PHARMACEUTICAL CO LTD [CN]; JIANG SHENG [CN]; LI SHANG [CN]; YAO ZHIYI [CN]; YAO YIWU [CN]; ZHANG FENG [CN]; CHAO YANG [CN]; YE HAI [CN]; CHEN MIN [CN]	Histone deacetylase inhibitors and synthetic method thereof and use thereof in manufacture of medicaments
<u>WO2013071055 A1</u> <u>20130516</u>	WELLSTAT DIAGNOSTICS LLC [US]; GOVERNMENT OF THE USA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH AND HUMAN SERVICES OFFICE OF TE [US]	Assay for diabetes-associated autoantibodies
<u>WO2013071047 A1</u> <u>20130516</u>	CHILDRENS MEDICAL CENTER [US]	Compositions and methods for in vitro transcription of rna
<u>WO2013070852 A2</u> <u>20130516</u>	UNIV EMORY [US]; ISTITUTO PASTEUR FOND CENCI BOLOGNETTI [IT]	Compounds and compositions used to epigenetically transform cells and methods related thereto
<u>WO2013067420 A1</u> <u>20130510</u>	TUMLIN JAMES A [US]; GALPHIN CLAUDE [US]; ROVIN BRAD [US]	Acth for treatment of kidney disease
<u>WO2013065914 A1</u> <u>20130510</u>	JEIL PHARMACEUTICAL CO LTD [KR]; CHO MYUNG SOO [KR]; YU HYEONG GON [KR]; KIM SANG JIN [KR]; PARK JUNG HYUN [KR]; KU SEUNG YUP [KR]; YOO DAE HOON [KR]; KIM MYUNG HWA [KR]; SOH DONG JUN [KR]; SHIM KYOO JUNG [KR]	Method for inducing differentiation from a cystic structure to retinal pigment epithelial cells
<u>WO2013065913 A1</u> <u>20130510</u>	VIROMED CO LTD [KR]; KIM JONG MOOK [KR]; JEONG JAE GYUN [KR]	Gene therapy for diabetic neuropathy using an hgf isoform
<u>WO2013065832 A1</u> <u>20130510</u>	NIPPI INC [JP]	Dpp-4 inhibitor
<u>WO2013063412 A2</u> <u>20130502</u>	MASSACHUSETTS INST TECHNOLOGY [US]	Methods of diagnosis and treatment of endoplasmic reticulum (er) stress-related conditions
<u>WO2013063313 A1</u> <u>20130502</u>	ISIS PHARMACEUTICALS INC [US]; FREIER SUSAN M [US]; BHANOT SANJAY [US]	Antisense modulation of gccr expression
<u>WO2013052965 A2</u> <u>20130411</u>	MIRAGEN THERAPEUTICS [US]; UNIV TEXAS [US]	Control of whole body energy homeostasis by microrna regulation
<u>WO2013048116 A2</u> <u>20130404</u>	KIM HOOJUNG [KR]	Erythropoietin-derived peptide and use therefor
<u>WO2013039996 A1</u> <u>20130321</u>	DANA FARBER CANCER INST INC [US]; SPIEGELMAN BRUCE M [US]; BOSTROM PONTUS [US]	Compositions and methods for brown fat induction and activity using fndc5

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013026575 A2 20130228</u>	ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; ULTIZYME INTERNATIONAL LTD [JP]; KOJIMA KATSUHIRO [JP]; MIORI KAZUSHIGE [JP]; SODE KOJI [JP]	Glucose oxidase
<u>WO2013021389 A2 20130214</u>	YEDA RES & DEV [IL]; HORNSTEIN ERAN [IL]; KREDO-RUSSO SHARON [IL]	Downregulation of mir-7 for promotion of beta cell differentiation and insulin production
<u>WO2013020372 A1 20130214</u>	SHANGHAI INST BIOL SCIENCES [CN]; Zhai Qiwei [CN]; Zhang Yi [CN]; Le Yingying [CN]	Methods and reagents for preventing and curing insulin resistance and diabetes mellitus
<u>WO2013016278 A2 20130131</u>	CHILDRENS MEDICAL CENTER [US]; KAGAN JONATHAN C [US]	Modulators of antiviral signaling pathways and therapeutic uses thereof
<u>WO2013013029 A1 20130124</u>	UNIV ILLINOIS [US]; PRABHAKAR BELLUR S [US]; VASU CHENTHAMARAKSHAN [US]; BHATTACHARYA PALASH [US]	Anti-clta4, anti-glut2 protein for the treatment of type 1 diabetes
<u>WO2013009143 A2 20130117</u>	SNU R&DB FOUNDATION [KR]; KIM YOUNG SOO [KR]; YU HYEONG GON [KR]; KIM KYUNG GON [KR]; KIM SANG JIN [KR]; YU JI YOUNG [KR]	Marker for diagnosing diabetic retinopathy
<u>WO2013006486 A2 20130110</u>	NGM BIOPHARMACEUTICALS INC [US]; LING LEI [US]; LINDHOUT DARRIN A [US]	Compositions, uses and methods for treatment of metabolic disorders and diseases
<u>WO2012170438 A2 20121213</u>	AMGEN INC [US]; LI YANG [US]; STEVENS JENNITTE [US]; KING CHADWICK TERENCE [CA]; FOLTZ IAN [CA]; KANNAN GUNASEKARAN [US]; YIE JUNMING [US]; HU SHAW-FEN SYLVIA [US]	Human antigen binding proteins that bind to a complex comprising ss-klotho and an fgf receptor
<u>WO2012138599 A2 20121011</u>	UNIV WASHINGTON STATE RES FDN [US]; HARDING JOSEPH W [US]; WRIGHT JOHN W [US]; BENOIST CAROLINE C [US]; KAWAS LEEN H [US]; WAYMAN GARY A [US]	Hepatocyte growth factor mimics as therapeutic agents
<u>WO2012138510 A1 20121011</u>	LILLY CO ELI [US]; BEIDLER CATHERINE BRAUTIGAM [US]; HEUER JOSEF GEORGE [US]; PETROVAN RAMONA JUDITA [US]	Antibodies that bind tgf-alpha and epiregulin
<u>WO2012119117 A1 20120907</u>	SENSULIN LLC [US]; UNIV TEXAS [US]; ANNAPRAGADA ANANTH [US]; DASGUPTA INDRANI [US]; TANIFUM ERIC [US]; SRIVASTAVA MAYANK [US]; ANALOUI MOSTAFA [US]	Vesicle compositions
<u>WO2012106427 A2 20120809</u>	UNIV SOUTHERN CALIFORNIA [US]; RODGERS KATHLEEN E [US]; DIZEREZA GERE S [US]	Methods for treating diabetic foot ulcers
<u>WO2012100010 A1 20120726</u>	UNIV CINCINNATI [US]; TSO PATRICK [US]; DAVIDSON SEAN [US]; WOODS STEPHEN [US]; WANG FEI [US]	Apolipoprotein aiv as an antidiabetic peptide
<u>WO2012098071 A1 20120726</u>	ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; CHEN MING-WEN	Medical hand-held device

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2012088519 A2</u> <u>20120628</u>	AMAZENTIS SA [CH]; ANDREAUX PENELOPE [CH]; SCHNEIDER BERNARD [CH]; RINSCH CHRISTOPHER L [CH]; SANDI CARMEN [CH]; AUWERX JOHAN [CH]; PIRINEN EIJA [CH]; THOMAS CHARLES [CH]; HOUTKOOPER RICHARDUS [CH]; BLANCO-BOSE WILLIAM [CH]; MOUCHIROUD LAURENT [CH]; GENOUX DAVID [CH]	Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
<u>WO2012085890 A1</u> <u>20120628</u>	METANOMICS HEALTH GMBH [DE]; BASF CHINA CO LTD [CN]; WIEMER JAN [DE]; REIN DIETRICH [DE]; PADBERG INKEN [DE]; SCHMITZ OLIVER [DE]; LIEBENBERG VOLKER [DE]; NIKIFOROVA VIKTORIA [DE]	Means and method for predicting diabetes
<u>WO2012080384 A1</u> <u>20120621</u>	ROCHE DIAGNOSTICS GMBH [DE]; HOFFMANN LA ROCHE [CH]; WANG WEN TSUNG; LIN HAO-CHI	Test tape device
<u>WO2012082950 A2</u> <u>20120621</u>	UNIV ROCHESTER [US]; HOCKING DENISE [US]; ROY DANIEL [US]	Chimeric fibronectin matrix mimetics and uses thereof
<u>WO2012070936 A1</u> <u>20120531</u>	LANTHOPEP B V [NL]; DE VRIES LOUWE [NL]; NELEMANS SIEGER ADRIAAN [NL]; RINCK RICK [NL]; ROKS ANTONIUS JACOBUS MARINUS [NL]; MOLL GERT NIKOLAAS [NL]	Novel angiotensin type 2 (at2) receptor agonists and uses thereof
<u>WO2012065362 A1</u> <u>20120524</u>	UNIV HONG KONG SCIENCE & TECHN [CN]; WANG ZHE [CN]; QI ROBERT ZHONG [CN]	Myomegalin variant 8 and uses thereof
<u>WO2012059873 A2</u> <u>20120510</u>	COVX TECHNOLOGIES IRELAND LTD [IE]; PFIZER [US]; ISHINO TETSUYA [US]; PALANKI MOORTHY SITHARAMAIAH SURIYANARAYANA [US]; VIOLAND BERNARD NORMAN [US]; DAS TAPAN KANTI [US]; HODGE TAMARA SHAFER [US]; LEVIN NANCY JANE [US]; PARSONS ERIN KRISTEN [US]	Anti-diabetic compounds
<u>ES2396073 A1</u> <u>20130219</u>	UNIV SANTIAGO COMPOSTELA [ES]	Metodo para inhibir el apetito
<u>ES2394331 A1</u> <u>20130130</u>	UNIV SANTIAGO COMPOSTELA [ES]	Uso de un péptido antigénico aislado derivado de la proteína s100-beta no unido a una molécula mhc de clase ii en la prevención, tratamiento, diagnóstico y/o seguimiento de la diabetes tipo i
<u>ES2394972 A1</u> <u>20130207</u>	UNIV SANTIAGO COMPOSTELA [ES]	Isolated antigen peptide derived from s100-beta protein, identification method and use thereof in the prevention, treatment, diagnosis and/or monitoring of type 1 diabetes
<u>ES2389547 A1</u> <u>20121029</u>	CONSEJO SUPERIOR INVESTIGACION [ES]	Bifidobacterium CECT 7765 and use thereof in the prevention and/or treatment of overweight, obesity and associated pathologies

Sistema Nervioso

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013124817 A2 20130829</u>	BRAINSTEM BIOTEC LTD [IL]	Micrornas for the generation of astrocytes
<u>WO2013119045 A1 20130815</u>	AJOU UNIV IND ACAD COOP FOUND [KR]	Neural differentiation of mesenchymal stem cells in thermosensitive hydrogel and composition for neural differentiation
<u>WO2013117930 A2 20130815</u>	ISIS INNOVATION [GB]	Diagnosing multiple sclerosis
<u>WO2013117742 A2 20130815</u>	SELMAJ KRZYSZTOF [PL]; SZCZEPANIK MARIAN [PL]	Pharmaceutical composition for the treatment of multiple sclerosis
<u>WO2013117713 A1 20130815</u>	QUEEN MARY & WESTFIELD COLLEGE [GB]	Reversal of senescence
<u>WO2013113755 A1 20130808</u>	FUNDACIO INST D INVESTIGACIO BIOMEDICA DE BELLVITGE IDIBELL [ES]; LYKERA BIOMED S A [ES]; UNIV BARCELONA AUTONOMA [ES]	Reagents and methods for the treatment of diseases based on the inhibition of calcineurin - nfat signalling pathway
<u>WO2013111578 A1 20130801</u>	PANASONIC CORP [JP]; SHIGA UNIVERSITY OF MEDICAL SCIENCE [JP]	Diagnosis method and diagnosis system for alzheimer's disease
<u>WO2013111045 A1 20130801</u>	ECOLE POLYTECH [CH]	Use of waste products for detecting amyloidogenic proteinaceous material in living mammals
<u>WO2013106572 A1 20130718</u>	UNIV ARIZONA [US]; SIERKS MICHAEL [US]; SHEN YONG [US]	Bispecific antibody fragments for neurological disease proteins and methods of use
<u>WO2013103966 A1 20130711</u>	UNIV COLORADO REGENTS [US]	Methods for the treatment of multiple sclerosis and other demyelinating disorders
<u>WO2013099806 A1 20130704</u>	TAO HEALTH LIFE PHARMA CO LTD [JP]	Target molecule to which amylospheroid binds and induces mature neuronal cell death, method and substance for inhibiting amylospheroid-induced neuronal cell death, and uses for said target molecule, method, and substance
<u>WO2013098364 A1 20130704</u>	DEUTSCHES KREBSFORSCH [DE]	Second generation virus-like particles (vlp) from epstein-barr viruses for vaccination purposes

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013097748 A1 20130704</u>	GENERON SHANGHAI CORP LTD [CN]	Uses of interleukin-22(il-22) in treating and preventing nerve damage diseases or neurodegenerative diseases
<u>WO2013092640 A1 20130627</u>	PASTEUR INSTITUT [FR]; CENTRE NAT RECH SCIENT [FR]; UNIV PARIS CURIE [FR]	Optineurin-derived polypeptides, their nucleic acids and uses thereof
<u>WO2013088441 A1 20130620</u>	YEDA RES & DEV [IL]	Human monocyte sub-population for treatment of central nervous system injury
<u>WO2013087911 A1 20130620</u>	SYNTHON BIOPHARMACEUTICALS B V [NL]	Compounds and methods for treating inflammatory diseases
<u>WO2013086443 A1 20130613</u>	AMGEN INC [US]	Agonistic human Icat antigen binding proteins and their use in therapy
<u>WO2013085893 A1 20130613</u>	IMMUNOMEDICS INC [US]	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
<u>WO2013082548 A1 20130606</u>	SAREPTA THERAPEUTICS INC [US]	Oligonucleotides for treating expanded repeat diseases
<u>WO2013082487 A1 20130606</u>	CHILDREN S HOSPITAL LOS ANGELES [US]	Afsc based therapies
<u>WO2013082417 A1 20130606</u>	ANTHROGENESIS CORP [US]; HERZBERG URI [US]	Treatment using placental stem cells
<u>WO2013074569 A1 20130523</u>	BOEHRINGER INGELHEIM INT [DE]; BROWN SUELLIN [US]; CANADA KEITH [US]; CHLEWICKI LUKASZ [US]; HOWELL MICHAEL [US]; MENNERICH DETLEV [DE]; WOSKA JR JOSEPH ROBERT [US]	Anti il-36r antibodies
<u>WO2013071119 A2 20130516</u>	GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]	Methods for treating, diagnosing and monitoring alzheimer's disease
<u>WO2013070079 A2 20130516</u>	VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG [NL]; STICHTING VU VUMC [NL]	Mirna in blood brain barrier of ms patients
<u>WO2013070076 A1 20130516</u>	UMC Utrecht HOLDING BV [NL]	Fusion protein comprising an interleukin 4 and interleukin 10
<u>WO2013068472 A1 20130516</u>	MERZ PHARMA GMBH & CO KGAA [DE]; EISELE KARL HEINZ [DE]	Modified neurotoxins with poly-glycine and uses thereof

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013068431 A1 20130516</u>	NOVARTIS FORSCHUNGSSTIFTUNG [CH]; CARONI PICO [CH]; ROSELLI FRANCESCO [IT]	New treatment for neurodegenerative diseases
<u>WO2013063383 A2 20130502</u>	WELLSTAT OPHTHALMICS CORP [US]	Vectors encoding rod-derived cone viability factor
<u>WO2013061163 A2 20130502</u>	BIOGEN IDEC INTERNAT NEUROSCIENCE GMBH [CH]; UNIV ZUERICH [CH]	Tdp-43 specific binding molecules
<u>WO2013049750 A1 20130404</u>	ROSSI DAVIDE [US]; GAIDANO GIANLUCA [US]; FOA ROBERT [US]; TROVAGENE INC [US]	Mutations in sf3b1 and chronic lymphocytic leukemia
<u>WO2013049362 A2 20130404</u>	US OF AMERICA AS REPRESENTED BY THE SECRETARY DEPT OF HEALTH & HUMAN SERVICES [US]	Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis.
<u>WO2013043933 A2 20130328</u>	AMGEN INC [US]; DELANEY JOHN M [US]; FANSLOW WILLIAM CHRISTIAN III [US]; KING CHADWICK TERENCE [CA]	Cd27l antigen binding proteins
<u>WO2013042053 A2 20130328</u>	UNIV WITWATERSRAND JHB [ZA]	Compounds for use in the treatment of alzheimer's disease
<u>WO2013040062 A2 20130321</u>	UNIV VANDERBILT [US]; AUNE THOMAS M [US]; CROOKE PHILIP S [US]; OLSEN NANCY J [US]; TOSSBERG JOHN T [US]	Characterizing multiple sclerosis
<u>WO2013025963 A2 20130221</u>	HARVARD COLLEGE [US]; CHILDRENS MEDICAL CENTER [US]; EGGAN KEVIN CARL [US]; WOOLF CLIFFORD J [US]; WAINGER BRIAN J [US]; ICHIDA JUSTIN K [US]; SON ESTHER YESDE [US]	Conversion of somatic cells into functional spinal motor neurons, and methods and uses thereof
<u>WO2013026794 A1 20130228</u>	NOVOZYMES [DK]; KJAER TANJA MARIA ROSENKILDE [DK]; ANDERSEN BIRGITTE [DK]	Novel immunomodulatory peptide
<u>WO2013021962 A1 20130214</u>	NAT UNIV CORP TOTTORI UNIV [JP]; HYPER BRAIN CO LTD [JP]; URAKAMI KATSUYA [JP]; KIMURA MIYAKO [JP]	Kit for diagnosing alzheimer's dementia by carbohydrate chain measurement of complement c3 protein, diagnostic marker, and detection method
<u>WO2013022717 A1 20130214</u>	NEUROPHAGE PHARMACEUTICALS INC [US]; WRIGHT JASON [US]; HITCHCOCK ANTONY [GB]; SUGAR FRANK [US]; DAVIES TIM [GB]; ADHIKARI SHREEKANT [US]; MENON NANDA [US]; FLORENCE QUENTIN [US]	Pure filamentous bacteriophage and methods of producing same
<u>WO2012140296 A1 20121018</u>	ARACLON BIOTECH SL [ES]; SARASA BARRIO MANUEL [ES]	Antibody, kit and method for determining amyloid peptides

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2012095432 A2 20120719</u>	INNATE PHARMA [FR]; GAUTHIER LAURENT [FR]; MASSACRIER CATHERINE [FR]; MOREL YANNIS [FR]; PATUREL CARINE [FR]; BONNAFOUS CECILE [FR]; ANDERSEN METTE DAHL [DK]; ROSSI BENJAMIN [FR]	Tlr3 binding agents
<u>WO2012093127 A2 20120712</u>	UNIV ZUERICH [CH]; CHARITE UNIVERSITAETS MEDIZIN [DE]; BECHER BURKHARD [CH]; HEPPNER FRANK [DE]	Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
<u>WO2012091138 A1 20120705</u>	DAINIPPON SUMITOMO PHARMA CO [JP]; HASHIMOTO MASAKAZU [JP]; NAKAGAWA HIROYUKI [JP]; AOKI MIKIO [JP]; TJERNBERG LARS O [SE]; WINBLAD BENGT [SE]	Diagnostic drug and diagnostic method for alzheimer's disease
<u>WO2012085282 A1 20120628</u>	MOLOGEN AG [DE]; SCHROFF MATTHIAS [DE]; KLEUSS CHRISTIANE [DE]; KAPP KERSTIN [DE]	Dna expression construct
<u>WO2012080518 A1 20120621</u>	NEURIMMUNE HOLDING AG [CH]; UNIV ZUERICH [CH]; MONTRASIO FABIO [CH]; BARENCO MONTRASIO MARIA GRAZIA [CH]; GRIMM JAN [CH]; NITSCH ROGER [CH]; HOCK CHRISTOPH [CH]; WELT TOBIAS [CH]; MCAFOOSE JORDAN [CH]; MAIER MARCEL [CH]	Human anti-sod1 antibodies
<u>WO2012082056 A1 20120621</u>	AUTISM BIODIAGNOSIS LTD [GB]; MOMENI NAGHI [SE]; PERSSON BENGT L [SE]	Novel biomarker and uses thereof in diagnosis, treatment of autism
<u>WO2012077649 A1 20120614</u>	DAINIPPON SUMITOMO PHARMA CO [JP]; WATANABE TAKAMASA [JP]; YOSHIMA TADAHIKO [JP]; MATTSSON MIKAEL [SE]; SARNEFALT ANNA [SE]; HASEZAKI TAKUYA [JP]	Human monoclonal antibody
<u>WO2012068405 A2 20120524</u>	ISIS PHARMACEUTICALS INC [US]; BENNETT C FRANK [US]; FREIER SUSAN M [US]; MALLAJOSYULA JYOTHI [US]	Modulation of alpha synuclein expression
<u>WO2012068170 A2 20120524</u>	LEE JAU-NAN; LEE TONY TUNG-YING [US]; LEE YUTA; TSAI EING-MEI	Generation of neural stem cells from human trophoblast stem cells
<u>WO2012064682 A1 20120518</u>	REGENERON PHARMA [US]; CLASSON BRENDAN J [US]; SKOKOS DIMITRIS [US]	Human antibodies to human tnf-like ligand 1a (tl1a)
<u>WO2012061448 A1 20120510</u>	BOEHRINGER INGELHEIM INT [DE]; BARRETT RACHEL REBECCA [US]; CANADA KEITH [US]; CATRON KATRINA MARY [US]; COPENHAVER ROBERT [US]; FREGO LEE EDWARD [US]; RAYMOND ERNEST LEE [US]; SINGH SANJAYA [US]; ZHU XIANGYANG [US]	Anti-il-23 antibodies

Sistema Inmune

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2012064682 A1 20120518</u>	REGENERON PHARMA [US]; CLASSON BRENDAN J [US]; SKOKOS DIMITRIS [US]	Human antibodies to human tnf-like ligand 1a (tl1a)
<u>WO2013130905 A1 20130906</u>	GILEAD BIOLOGICS INC [US]	Antibodies to matrix metalloproteinase 9
<u>WO2013123996 A1 20130829</u>	ASTRAZENECA UK LTD [GB]; WELLS TED [GB]; HENDERSON DUNCAN [GB]; JACKSON CLIVE [GB]; GEBHARDT FRANK [DE]	Novel sirna inhibitors of human icam-1
<u>WO2012054509 A2 20120426</u>	DANA FARBER CANCER INST INC [US]; CANTOR HARVEY [US]; KIM HYE-JUNG [US]; LU LINRONG [CN]	Discovery of regulatory t cells programmed to suppress an immune response
<u>WO2012054565 A1 20120426</u>	GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]; BOURHIS ERIC [US]; COCHRAN ANDREA [US]; ZHANG YINGNAN [US]	Methods and compositions for modulating the wnt pathway
<u>WO2013120618 A1 20130822</u>	PHARMA ZENTRALE GMBH [DE]	Recombinant escherichia coli strains
<u>WO2013120554 A1 20130822</u>	NOVO NORDISK AS [DK]	Antibodies that bind peptidoglycan recognition protein 1
<u>WO2013120553 A1 20130822</u>	NOVO NORDISK AS [DK]	Antibodies that bind and block triggering receptor expressed on myeloid cells-1 (trem-1)
<u>WO2013119716 A1 20130815</u>	GENENTECH INC [US]; HOFFMANN LA ROCHE [CH]	Compositions and methods for using csf1r inhibitors
<u>WO2013117860 A1 20130815</u>	UNIV LILLE II DROIT & SANTE; INST NAT SANTE RECH MED; CENTRE NAT RECH SCIENT [FR]; CT HOSPITALIER REGIONAL UNIVERSITAIRE DE LILLE	28 kda gst proteins from schistosoma for the use thereof in the treatment of inflammatory autoimmune diseases generating a th1 and/or th17 response
<u>WO2013116822 A1 20130808</u>	LIPELLA PHARMACEUTICALS INC [US]	Methods and compositions for treating gastric disorders
<u>EP2620162 A1 20130731</u>	LIFE SCIENCE INKUBATOR BETR S GMBH & CO KG [DE]	Enzyme-polymer conjugate for endotoxin detoxification
<u>WO2013109185 A1 20130725</u>	VILARA AB [SE]	Novel antibodies

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013108760 A1 20130725</u>	MEDICAL CORP DOAI KAI [JP]; NIPPON DENTAL UNIVERSITY [JP]	Composition useful in treating pain or rheumatoid arthritis, method for treating pain or rheumatoid arthritis using same, composition for lowering cytokine concentration and method for lowering cytokine concentration using same
<u>WO2013105721 A1 20130718</u>	CATHOLIC UNIV IND ACAD COOP [KR]	Rheumatoid arthritis diagnosis kit
<u>WO2013105013 A1 20130718</u>	COVX TECHNOLOGIES IRELAND LTD [IE]	Mutant antibodies and conjugation thereof
<u>WO2013103783 A1 20130711</u>	SANOFI US [US]	Murine il-13 antibodies
<u>WO2013102042 A2 20130704</u>	ABBVIE INC [US]	Dual variable domain immunoglobulins against il-13 and/or il-17
<u>WO2013098441 A1 20130704</u>	UNIV SEVILLA [ES]	Determination of immunogenic gluten peptides in human samples
<u>WO2013098364 A1 20130704</u>	DEUTSCHES KREBSFORSCH [DE]	Second generation virus-like particles (vlp) from epstein-barr viruses for vaccination purposes
<u>WO2013097709 A1 20130704</u>	XU HANMEI [CN]	Integrin blocker polypeptide and use thereof
<u>WO2013091273 A1 20130627</u>	CHINA NAT RES INST OF FOOD AND FERMENTATION IND [CN]; CAI MUYI [CN]; GU RUIZENG [CN]; YI WEIXUE [CN]; LIN FENG [CN]; MA YONG [CN]; DONG ZHE [CN]; PAN XINGCHANG [CN]; MA YONGQING [CN]; XU YAGUANG [CN]; LU JUN [CN]; JIN ZHENTAO [CN]; CHEN LIANG [CN]; LIU WENYING [CN]	Method for producing wheat glutamine peptide
<u>WO2013090989 A1 20130627</u>	CSL LTD [AU]	Method of treating inflammatory bowel disease
<u>WO2013088140 A2 20130620</u>	ISIS INNOVATION [GB]	Biomarker and use thereof. Tenascin and use thereof in rheumatoid arthritis
<u>WO2013087913 A1 20130620</u>	SYNTHON BIOPHARMACEUTICALS B V [NL]	Compounds and methods for treating inflammatory diseases
<u>WO2013087911 A1 20130620</u>	SYNTHON BIOPHARMACEUTICALS B V [NL]	Compounds and methods for treating inflammatory diseases

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013087699 A1 20130620</u>	HOFFMANN LA ROCHE [CH]; FERTIG GEORG [DE]; FIDLER ALEXANDER [DE]; KALUZA KLAUS [DE]; RIES CAROLA [DE]; SEEBER STEFAN [DE]; THOMAS MARLENE [DE]	Antibodies against human csf-1r and uses thereof
<u>WO2013085893 A1 20130613</u>	IMMUNOMEDICS INC [US]	Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
<u>WO2013085851 A2 20130613</u>	BIO RAD LABORATORIES [US]	Recombinant deamidated gliadin antigen
<u>WO2013083866 A1 20130613</u>	UNIV PABLO DE OLAVIDE [ES]; FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD [ES]	Use of anti-beta-lactoglobulin antibodies in the diagnosis and monitoring of celiac disease
<u>WO2013083338 A1 20130613</u>	FOND ISTITUTO INSUBRICO DI RICERCA PER LA VITA [IT]	New proteases able to hydrolyze gluten peptides and proteins at acidic ph, from the actinomycete actinoallomurus
<u>WO2013082487 A1 20130606</u>	CHILDREN S HOSPITAL LOS ANGELES [US]	Afsc based therapies
<u>WO2013080050 A2 20130606</u>	UNIVERSITAETSKLINIKUM ERLANGEN [DE]; ABBVIE DEUTSCHLAND GMBH & CO KG [DE]	Methods and compositions for determining responsiveness to treatment with a tnf-alpha inhibitor
<u>WO2013079721 A1 20130606</u>	BERGEN TEKNOLOGIOVERFOERING AS [NO]	Marker and method for diagnosing diarrhea syndrome
<u>WO2013078378 A1 20130530</u>	AMGEN INC [US]	Methods of treatment using an antibody against interferon gamma
<u>WO2013075027 A2 20130523</u>	EMERGENT PRODUCT DEV SEATTLE [US]; LOFQUIST ALAN K [US]; MISHER LYNDA [US]; ADAMO JEFFREY B [US]; FANG HANG [US]; RAVIKUMAR PADMA [US]	Anti-sil6xr complex binding domains and methods of use
<u>WO2013074816 A2 20130523</u>	UNIV PITTSBURGH [US]	Novel inhibitors of nox1
<u>WO2013073041 A1 20130523</u>	DNA CHIP RESEARCH INC [JP]; UNIV KEIO [JP]; UNIV SAITAMA MEDICAL [JP]; TAKEUCHI TSUTOMU [JP]; AMANO KOICHI [JP]; ISHIZAWA YOHEI [JP]; NAKAMURA SEIJI [JP]; TANINO MOTOHIKO [JP]; HATA YUKO [JP]	Method for determining rheumatoid arthritis activity indicator, and biomarker used therein
<u>WO2013070076 A1 20130516</u>	UMC Utrecht HOLDING BV [NL]	Fusion protein comprising an interleukin 4 and interleukin 10
<u>WO2013068902 A1 20130516</u>	PFIZER [US]	Methods of treating inflammatory disorders using anti-m-csf antibodies

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2013067098 A1 20130510</u>	APEXIGEN INC [US]	Anti-kdr antibodies and methods of use
<u>WO2013059732 A1 20130425</u>	NESTEC SA [CH]; PRINCEN FRED [US]; LOCKTON STEVEN [US]; CRONER LISA J [US]; FLETCHER FREDERICK A [US]; STOCKFISCH THOMAS [US]; SINGH SHARAT [US]	Methods for improving inflammatory bowel disease diagnosis
<u>WO2013056250 A2 20130418</u>	UNIV WAYNE STATE [US]	Cxcr4 inhibiting carriers for nucleic acid delivery
<u>WO2013053751 A1 20130418</u>	SANOFI SA [FR]; REGENERON PHARMA [US]	Compositions for the treatment of rheumatoid arthritis and methods of using same
<u>WO2013052099 A2 20130411</u>	MAZMANIAN SARKIS K [US]; KASPER DENNIS L [US]; LEE SUNG-EUN [US]	Generation of psa-only producing mutant strain
<u>WO2013045737 A1 20130404</u>	UNIV VALLADOLID [ES]	Immunogenic gluten peptides and uses thereof
<u>WO2013043070 A2 20130328</u>	TECHNOPHAGE INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA SA [PT]	Anti-tumor necrosis factor-alpha agents and uses thereof
<u>WO2013034795 A1 20130314</u>	CONSEJO SUPERIOR INVESTIGACION [ES]; IMP COLLEGE LONDON [GB]; SANCHEZ GARCIA BORJA [ES]; MARGOLLES BARROS ABELARDO [ES]; BERNARDO ORDIZ DAVID [GB]; KNIGHT STELLA C [GB]; HAFID OMAR [GB]	Peptide secreted by lactobacillus plantarum with immunomodulating function
<u>WO2013032032 A1 20130307</u>	EISAI R&D MAN CO LTD [JP]; SAKAMOTO YOSHIMASA [JP]; NISHIMURA MIYUKI [JP]; KAWANO TETSU [JP]; SAWA YUKIHISA [JP]; IMAI TOSHIRO [JP]	Anti-human xcr1 antibodies
<u>WO2013026794 A1 20130228</u>	NOVOZYMES [DK]; KJAER TANJA MARIA ROSENKILDE [DK]; ANDERSEN BIRGITTE [DK]	Novel immunomodulatory peptide
<u>WO2013008171 A1 20130117</u>	GLENMARK PHARMACEUTICALS SA [CH]; ATTINGER ANTOINE [CH]; BLEIN STANISLAS [CH]; BACK JONATHAN ALBERT [CH]; LISSILAA RAMI [CH]; HOU SAMUEL [CH]	Antibodies that bind to ox40 and their uses
<u>WO2013003930 A1 20130110</u>	UNIV RIO DE JANEIRO [BR]; LOBO BORGES HELENA [BR]; COLLA SOLETTI ROSSANA [BR]; SIFFERT PEREIRA DE SOUZA HEITOR [BR]	Initiators, method and kit for the differential diagnosis of crohn's disease and ulcerative rectocolitis by means of immunohistochemical labelling of the proteins b-catenin and retinoblastoma
<u>WO2013007596 A2 20130117</u>	NOVOZYMES AS [DK]; MARIA ROSENKILDE KJAER TANJA [DK]; ANDERSEN BIRGITTE [DK]; SIDELMANN BRINCH KAROLINE [DK]	Oral treatment of inflammatory bowel disease
<u>WO2012174001 A1 20121220</u>	ABGENOMICS COOPERATIEF U A [NL]; BASSARAB STEFAN [DE]; ENENKEL BARBARA [DE]; GARIDEL PATRICK [DE]; SCHOTT HEIDRUN [DE]; SINGH SANJAYA [US]; LITZENBURGER TOBIAS [DE]	Anti-psgl-1 antibodies and uses thereof

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
WO2012168199 A1 20121213	NOVO NORDISK AS [DK]; ZAHN STEFAN [DK]; ZEUTHEN LOUISE HJERRILD [DK]; HANSEN ANKER JON [DK]; KJAERGAARD KRISTIAN [DK]; LUND SOEREN [DK]	Therapeutic antibodies
WO2012167077 A1 20121206	UNIV CALIFORNIA [US]; SELSTED MICHAEL E [US]; TRAN DAT Q [US]	Blockade of inflammatory proteases with theta - defensins
WO2012113802 A1 20120830	BASILEA PHARMACEUTICA AG [CH]; LANE HEIDI ALEXANDRA [CH]; BACHMANN FELIX [CH]	Use of acetylated tubulin as a biomarker of drug response to furazanobenzimidazoles
WO2012110968 A2 20120823	NOVARTIS AG [CH]; UNIV ZUERICH [CH]; RUEHL ANNE [CH]; ROGLER GERHARD [CH]; SCHARL MICHAEL [CH]	Treatment of fistulizing crohn's disease
WO2012103345 A1 20120802	ABBOTT LAB [US]; CORREIA IVAN R S [US]; FUJIMORI TARO [US]; HRUSKA MATTHEW W [US]; PAULSON SUSAN KAYE [US]	Compositions containing glycosylated antibodies and uses thereof
WO2012101157 A1 20120802	PHARMASURGICS IN SWEDEN AB [SE]; MAHLAPUU MARGIT [SE]; BJOERN CAMILLA [SE]; SJOESTRAND VERONIKA [SE]; WALSE BJOERN [SE]; SVENSSON BO [SE]	Human lactoferrin derived peptides and there use
WO2012097238 A2 20120719	FIVE PRIME THERAPEUTICS INC [US]; WONG BRIAN [US]; GOSLING JENNIFA [US]	Il-27 antagonists for treating inflammatory diseases
WO2012095432 A2 20120719	INNATE PHARMA [FR]; GAUTHIER LAURENT [FR]; MASSACRIER CATHERINE [FR]; MOREL YANNIS [FR]; PATUREL CARINE [FR]; BONNAFOUS CECILE [FR]; ANDERSEN METTE DAHL [DK]; ROSSI BENJAMIN [FR]	Tlr3 binding agents
WO2012092612 A1 20120705	TAKEDA PHARMACEUTICAL [JP]; ELIAS KATHLEEN ANN [US]; LANDES GREGORY [US]; SINGH SHWETA [US]; KORVER WOUTER [US]; DRAKE ANDREW WALLING [US]; HAAK-FRENDSCHO MARY [US]; SNELL GYORGY PAL [US]; BHASKAR VINAY [US]	Anti-cd38 antibodies
WO2012089867 A2 20120705	UNIV SEVILLA [ES]; SOUSA MARTIN CAROLINA [ES]; COMINO MONTILLA ISABEL [ES]; REAL CALDERON ANA [ES]	Method for selecting cereal seeds suitable for consumption by coeliac patients
WO2012085282 A1 20120628	MOLOGEN AG [DE]; SCHROFF MATTHIAS [DE]; KLEUSS CHRISTIANE [DE]; KAPP KERSTIN [DE]	Dna expression construct
WO2012085182 A1 20120628	FABRE PIERRE DERMO COSMETIQUE [FR]; UNIV PARIS CURIE [FR]; CENTRE NAT RECH SCIENT [FR]; LEBARON PHILIPPE [FR]; BOURRAIN MURIEL [FR]; CASTEX-RIZZI NATHALIE [FR]; NGUYEN THIEN [FR]	Novel bacterium and extracts of said bacterium and the use of same in dermatology
WO2012088265 A1 20120628	SELEXYS PHARMACEUTICALS CORP; OKLAHOMA MED RES FOUND; ROLLINS SCOTT [US]; ALVAREZ RICHARD [US]; ROTHER RUSSELL [US]; KAWAR ZIAD S [US]; MCEVER RODGER P [US]	Anti-p-selectin antibodies and methods of their use and identification
WO2012088094 A2 20120628	ABBOTT LAB [US]; HSIEH CHUNG-MING [US]	Il-1 binding proteins

Nº DE PUBLICACIÓN	SOLICITANTE	CONTENIDO TÉCNICO
<u>WO2012080754 A2 20120621</u>	GENETIC ANALYSIS AS [NO]; VEBOE HEIDI [NO]; RUDI KNUT [NO]; ROWE DANIEL [GB]; SEKELJA MONIKA [NO]	Oligonucleotide probe set and methods of microbiota profiling
<u>WO2012076668 A1 20120614</u>	NEOVACS [FR]; GROUARD-VOGEL GERALDINE [FR]; DHELLIN OLIVIER [FR]; FANGET BERNARD [FR]; VANDEPAPELIERE PIERRE [BE]	Strongly inactivated and still highly immunogenic vaccine and process of manufacturing thereof
<u>WO2012077649 A1 20120614</u>	DAINIPPON SUMITOMO PHARMA CO [JP]; WATANABE TAKAMASA [JP]; YOSHIMA TADAHIKO [JP]; MATTSSON MIKAEL [SE]; SARNEFALT ANNA [SE]; HASEZAKI TAKUYA [JP]	Human monoclonal antibody
<u>WO2012071561 A2 20120531</u>	ALDER BIOPHARMACEUTICALS INC [US]; SMITH JEFFREY T L [US]	Anti-il-6 antibodies for the treatment of anemia
<u>WO2012071554 A2 20120531</u>	ALDER BIOPHARMACEUTICALS INC [US]; SMITH JEFFREY T L [US]	Anti-il-6 antibodies for the treatment of oral mucositis
<u>WO2012069433 A2 20120531</u>	GLAXO GROUP LTD [GB]; BEMBRIDGE GARY PETER [GB]; CHUNG CHUN-WA [GB]; FEENEY MARIA [GB]; FORD SUSANNAH KAREN [GB]; KIRBY IAN [GB]; MCADAM RUTH [GB]	Antigen binding proteins to oncostatin m (osm)
<u>WO2012068540 A2 20120524</u>	IMAI TOSHIO [JP]; KLINE BRAD [US]; KAWANO TETSU [JP]; GRASSO LUIGI [US]; SAKAMOTO YOSHIMASA [JP]; SPIDEL JARED [US]; NISHIMURA MIYUKI [JP]; MURMOTO KENZO [JP]; HORIZOE TASTUO [JP]	Neutralizing anti-ccl20 antibodies
<u>WO2012068470 A2 20120524</u>	IDERA PHARMACEUTICALS INC [US]; KANDIMALLA EKAMBAR R [US]; WANG DAQING [US]; NOWAK IRENEUSZ [US]; AGRAWAL SUDHIR [US]	Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
<u>WO2012065212 A1 20120524</u>	KO SAI YING [CN]	Anti-inflammatory compositions
<u>WO2012061448 A1 20120510</u>	BOEHRINGER INGELHEIM INT [DE]; BARRETT RACHEL REBECCA [US]; CANADA KEITH [US]; CATRON KATRINA MARY [US]; COPENHAVER ROBERT [US]; FREGO LEE EDWARD [US]; RAYMOND ERNEST LEE [US]; SINGH SANJAYA [US]; ZHU XIANGYANG [US]	Anti-il-23 antibodies
<u>WO2012081271 A1 20120621</u>	KAYTEEBIO CO & LTD [JP]; TSUZAKA KENSEI [JP]	Novel test method for rheumatoid arthritis and kit for rheumatoid arthritis test
<u>WO2012071042 A1 20120531</u>	GOVERNMENT OF THE U S A REPRESENTED BY THE SECRETARY DEPT OF HEALTH & HUMAN SERVICES [US]; RIVER JUAN [US]; CHARLES NICOLAS [FR]	Compositions and methods for treating or preventing lupus

Noticias

Taller sobre “Patentabilidad en el campo técnico de la biotecnología”

La Academia Europea de Patentes, órgano de la Oficina Europea de Patentes (EPO), y la Oficina Española de Patentes y Marcas (OEPM) organizan un taller sobre “Patentabilidad en el campo técnico de la biotecnología” como plataforma de discusión donde intercambiar experiencias entre ambas Oficinas.

La jornada se celebrará en la OEPM el próximo 13 de noviembre y contará con la participación de la empresa *BIOPOLIS* y examinadores especializados en biotecnología tanto de la EPO como de la OEPM.

[Más información.](#)

Adhesión de España al Tratado de Derecho de Patentes

El 6 de agosto se depositó ante la Organización Mundial de la Propiedad Intelectual (OMPI) el instrumento de adhesión de España al Tratado de Derecho de Patentes (PLT), adoptado en Ginebra el 1 de Junio de 2000. Este Tratado tendrá efectos en España a partir del 6 de noviembre de 2013.

El PLT pretende racionalizar y armonizar los requisitos formales establecidos para la presentación de las solicitudes de patentes y su mantenimiento.

Las disposiciones del PLT remiten en la medida de lo posible a las del Tratado de Cooperación en materia de Patentes (PCT) para evitar que se creen distintas normas nacionales sobre las formalidades de patentes en relación con las solicitudes nacionales e internacionales.

Se espera que la armonización de los diferentes procedimientos nacionales impulse el acceso a la protección por patente en todo el mundo, propiciando una reducción de los costes.

[Más información.](#)

